GSBR-1290 for Obesity
(ACCESS II Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use medications intended to promote weight loss within 6 months before the trial.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use medications intended to promote weight loss within 6 months before joining the study.
What data supports the effectiveness of the treatment GSBR-1290 for obesity?
The research highlights that losing even 5% of body weight can have significant health benefits, and new medications for obesity treatment have been gaining interest. Although the studies focus on surgical methods like gastric bypass, they emphasize the importance of effective obesity treatments, suggesting that new therapies like GSBR-1290 could be promising.12345
What is the purpose of this trial?
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various GSBR-1290 dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 36-week period.
Eligibility Criteria
This trial is for individuals who are living with obesity or overweight and have at least one weight-related health issue. Participants will also be following a diet and exercise plan during the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive various GSBR-1290 dose regimens or placebo, in addition to diet and exercise
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- GSBR-1290
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Lead Sponsor